Intravail(R) Drug Delivery Technology Provides Unmatched Non-Invasive Delivery Of An Anti-Obesity Peptide

Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil demonstrating that its Intravail(R) formulation technology provides unmatched non-invasive delivery of the OB-3 peptide, a peptide previously shown to control weight gain and glucose levels in an animal model of diabetes. The results of the study, presented by Dr.

More: continued here

Filed under: Endocrinology on November 21st, 2008